Retrospective Analysis Comparing the Effectiveness of Epoetin Alfa and Darbepoetin Alfa in Cancer Related and Chronic Kidney Disease Related Anemia Patients

Authors

  • Huiqun Qian

DOI:

https://doi.org/10.61173/ywd0by09

Keywords:

Epoetin Alfa, Darbepoetin Alfa, thrombo-embolic events (TEEs), Anemia, Cancer, Chronic Kidney Disease

Abstract

This retrospective analysis compares Epoetin Alfa and Darbepoetin Alfa in the treatment of patients with anaemia with cancer and anaemia with chronic kidney disease. Both erythropoiesis-stimulating agents (ESAs) stimulate erythropoiesis by modelling the natural hormone erythropoietin. Epoetin Alfa and Darbepoetin Alfa have significant structural and pharmacokinetic differences. Epoetin Alfa has a shorter half-life and needs to be administered more frequently, whereas Darbepoetin Alfa has a longer half-life and can be administered less frequently. However, they both increase the risk of thromboembolic events (TEE). This review explores the mechanisms of increased risk of TEE, evaluates clinical data, and discusses strategies to reduce risk. Clinical evidence suggests that Darbepoetin Alfa has a lower incidence of TEE compared to Epoetin Alfa. Individualisation of medication, regular haemoglobin monitoring and thromboprophylaxis in high-risk patients are essential to optimise treatment. The paper highlights the necessity of further research into safer alternatives. In summary, darbepoetin alfa may be a priority for stable patients due to its pharmacokinetic advantages and reduced risk of TEE. This article provides options to healthcare professionals for prescribing the drug and provides ideas for subsequent research directions.

References

[1] Locatelli F, Canaud B. Dialysis adequacy today: a European perspective. Nephrology Dialysis Transplantation. 2012 Aug 1;27(8):3043-8.

[2] Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PloS one. 2014 Jan 2;9(1):e84943.

[3] Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero JJ. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clinical kidney journal. 2020 Oct;13(5):821-7.

[4] Wanchoo R, Jhaveri KD, Fishbane S. Treatment with Erythropoiesis Stimulating Agents in Patients with Chronic Kidney Disease Complicated by Cancer. Journal of Onco- Nephrology. 2017 May;1(2):81-6.

[5] Corinaldesi G. Platelet activation in cardiovascular disease. Blood. 2011 Nov 18;118(21):5242.

[6] Fishbane S. The role of erythropoiesis-stimulating agents in the treatment of anemia. Am J Manag Care. 2010 Mar 1;16(Suppl Issues):S67-73.

[7] Allen G, Kruger A, Juneja R, Passaris G, Barbara JA. Improved haemoglobin levels with reduced frequency of administration of epoetin alfa. Renal Society of Australasia Journal. 2012 Nov 1;8(3):158.

[8] Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ, European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney international. 2002 Dec 1;62(6):2167-75.

[9] Fibben KS, Lam WA, Zhang DY, Kemp ML, Wood DK, Eiffrig E. Visualizing Sickle Cell Disease Whole Blood Flow and Viscosity through Modifications to Hemoglobin Levels from a Simple Blood Transfusion. Blood. 2021 Nov 23;138:3244.

[10] Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood, The Journal of the American Society of Hematology. 2013 Sep 26;122(13):2176-84.

[11] Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The Tromsø study. haematologica. 2010 Feb;95(2):270.

[12] Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ, European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney international. 2001 Aug 1;60(2):741-7.

[13] Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. The Oncologist. 2005 Sep 1;10(8):642-50.

[14] Bhat S, Nguyen K, Yee J, Besarab A, Poirier W, Frinak S, Holcomb J. 28: Efficacy of Darbepoetin Alfa (DA) in Hemodialysis (HD) Patients. American Journal of Kidney Diseases. 2008;4(51):B34.

[15] Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood, The Journal of the American Society of Hematology. 2017 Oct 19;130(16):1795-9.

[16] Sabir S, Khan YH, Khatoon M, Noreen R, Mallhi TH, Jabeen N. Effect of erythropoiesis stimulating agents on clinical outcomes in breast cancer patients: A systematic review of randomised controlled trials. J Coll Physicians Surg Pak. 2020 Mar 1;30(3):292-8.

[17] Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T. Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐ induced anemia and mortality: Individual patient data from J apanese randomized, placebo‐controlled trials. Cancer Science. 2013 Apr;104(4):481-5.

[18] Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. The Oncologist. 2007 Jun 1;12(6):727- 37.

[19] Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Therapeutics and Clinical Risk Management. 2020 Apr 8:245-59. Dean&Francis Huiqun Qian

[20] Park B. Jesduvroq Approved for Anemia of CKD in Patients on Dialysis. Clinical Advisor. 2023 Feb 7:NA-.

[21] T-Cells CA. 2023. Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis. Retrieved from [https://www.gsk.com/en-gb/media/ press-releases/jesduvroq-daprodustat-approved-by-us-fda-foranaemia-of-chronic-kidney-disease-in-adults-on-dialysis/]

Downloads

Published

2025-06-26

Issue

Vol. 3 No. 3 (2025): Volume 3, Issue 3

Section

Articles

License

Copyright (c) 2025 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.